News

During a Targeted Oncology Case-Based Peer Perspectives event, Todd Bauer, MD, medical oncologist, Tennessee Oncology, discussed the results from clinical trials that include patients with RET-altered lung cancer to determine a treatment strategy for a 59-year-old patient.

During a virtual Targeted Oncology Case-Based Peer Perspectives event, Dr. Tanios Bekaii-Saab discussed the chemotherapy and targeted treatment options available for the treatment of patients with metastatic colorectal cancer with participating oncologists.

Ken Kato, MD discusses the outcomes of the phase 3 KEYNOTE-590 study on esophageal cancer.

In an interview with Targeted Oncology, Andrea Apolo, MD discussed the impact of the combination of nivolumab and cabozantinib as a new treatment for patients with advanced renal cell carcinoma.

The FDA has granted an accelerated approval to tepotinib for the treatment of adult patients with metastatic non–small cell lung cancer who harbor a MET exon 14 skipping alteration.

A tumor-agnostic approach in which treatment is developed based on a tumor’s genetic and molecular features without regard to the cancer type or primary tumor location in the body, is the focus of the National Cancer Institute -MATCH trial.

This past year, 2020, will go down as a practice-changing one for the treatment of esophageal cancer, said Yelena Y. Janjigian, MD.

During a Targeted Oncology Case-Based Peer Perspectives event, Sara M. Tolaney, MD, MPH, discussed therapies available for the treatment of a 42-year-old woman with HER2-positive breast cancer.

The treatment landscape of genitourinary malignancies has seen tremendous growth in the last decade with advancements in prostate, bladder, and urothelial cancers.

The first-generation Bruton tyrosine kinase inhibitor ibrutinib has long been of interest in treating patients with primary diffuse large B-cell lymphoma of the central nervous system due to the disease’s reliance on chronic active B-cell receptor signaling.

Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, talks about the use of carfilzomib, dexamethasone, and daratumumab as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.

Neoadjuvant atezolizumab followed by surgery led to a major pathologic response in 21% of patients with resectable stage IB-IIIB non–small cell lung cancer, according to findings from the primary analysis of the LCMC3 trial.

New guidelines from the National Comprehensive Cancer Network provide information on proper coronavirus disease 2019 vaccination practices for providers treating patients with cancer.

The FDA has granted an Orphan Drug Designation to the novel Bcl-2 inhibitor, APG-2575, for the treatment of patients with follicular lymphoma.

A Biologics License Application was accepted by the FDA for BAT1706, a monoclonal antibody and proposed biosimilar of bevacizumab, which will be considered for the treatment of multiple solid tumor indications.

Research suggests that younger patients with small cell lung cancer perform better on immunotherapy compared with older patients.

Tislelizumab improved overall survival compared with investigator’s choice of chemotherapy in patients with advanced unresectable or metastatic esophageal squamous cell carcinoma who have received prior systemic therapy.

The FDA has granted an Orphan Drug Designation to the novel small molecule chemotherapeutic uttroside-B for the treatment of patients with hepatocellular carcinoma.

The role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia is supported by clinical trial research. During a Targeted Oncology Case-Based Peer Perspectives Roundtable event, Peter Hillmen, MB ChB, PhD, provided evidence around acalabrutinib for the case of a 61-year-old woman.

Patients with mantle cell lymphoma and primary gastrointestinal involvement have similar outcomes to those with secondary gastrointestinal involvement, according to results from one of the largest known studies of gastrointestinal mantle cell lymphoma.

An Orphan Drug Designation was granted by the FDA to ilixadencel as use for the treatment of patients with soft tissue sarcoma.

Ecaterina E. Ileana Dumbrava, MD, provides background information on a phase 1/2 study of the agent alone and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors.

In an interview with Targeted Oncology following a tweet chat, Mark Lewis, MD, discussed the key takeaways from the discussion and highlighted both the role of immunotherapy in metastatic colorectal cancer and the management of toxicities associated with chemoimmunotherapy regimens.

Multiple PI3K inhibitors are approved for the treatment of patients with follicular lymphoma in the relapsed or refractory setting, but these targeted treatments are usually given indefinitely, leading to toxicity and increased cost for patients.

Her appointment comes during the coronavirus disease 2019 vaccination push.

The FDA granted a Fast Track designation to the humanized PD-1 monoclonal antibody toripalimab for the first-line treatment of patients with mucosal melanoma.

JAK inhibitors designed for the treatment of myelofibrosis address the splenic response and constitutional symptoms associated with the disease, but the agents are inherently myelosuppressive and can exacerbate anemia and thrombocytopenia.

In an interview with Targeted Oncology, Senthil Damodaran, MD, PhD, discussed the need for an ESR1-targeted agent for the postmenopausal women with ESR1-positive, locally advanced or metastatic ER-positive/HER2-negative breast cancer.

This week, the FDA granted Priority Review designation to 4 therapies. The designations were across multiple malignancies and cancer-related conditions, including for patients with post-transplant complications, gastric/gastroesophageal junction and esophageal adenocarcinoma, as well as with squamous cell carcinoma of the anal canal.

The FDA has accepted a Biologics License Application for retifanlimab, an investigational intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who have progressed on or who are intolerant of platinum-based chemotherapy and has granted the BLA a Priority Review.